Apply to trial NCT05620771

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The immunotherapy consists of a standard-of-care treatment with Atezolizumab and Bevacizumab. Treatment with tyrosine kinase inhibitors consists of standard-of-care Lenvatinib or Cabozantinib.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening